Plasma pharmacokinetics of adriamycin and adriamycinol: implications for the design of in vitro experiments and treatment protocols.

The plasma pharmacokinetics of Adriamycin and adriamycinol following a 15-min infusion of 75 mg/sq m of Adriamycin were studied in ten patients previously untreated with Adriamycin. The disappearance kinetics of Adriamycin could adequately be described by a biexponential equation with an initial half-life of 8-min and a terminal half-life of 30 hr. The major drug exposure (area under the concentration-time curve) occurs during the terminal phase where drug concentrations are generally less than 10(-7) M (0.05 micrograms/ml). An improvement in the high-performance liquid chromatography sensitivity facilitated the determination of the terminal phase. The plasma kinetics of adriamycinol, the major and only known active metabolite of Adriamycin, show a rapid initial increase in plasma concentration followed by a slow decline which parallels that of Adriamycin during the terminal phase. The relative drug exposure of adriamycinol to Adriamycin was approximately 50%. The relationship between the measured plasma drug levels and free drug available for distribution into tissues was studied by comparing the plasma binding characteristics of Adriamycin and adriamycinol. A constant 20 to 25% of the total plasma concentrations of both Adriamycin and adriamycinol was freely diffusible over the whole range of observed concentrations, 20 nM to 2 microM. Thus, the free drug exposure (area under the concentration-time curve) of tumor and host tissues in vivo can be determined from these plasma measurements, since the free drug exposures in plasma and in extracellular fluid are equivalent. These results can also serve as a guide for the design of clinically relevant in vitro studies of Adriamycin and adriamycinol. The pharmacokinetic parameters determined in this study have been used to simulate plasma concentration-time courses for a variety of Adriamycin treatment schedules. Alternatives are suggested which reduce peak plasma Adriamycin concentration while antitumor area under the concentration-time curve is maintained.

[1]  J. Gross,et al.  Preliminary pharmacokinetic model for adriamycin (NSC-123127). , 1975, Cancer chemotherapy reports.

[2]  July , 1890, The Hospital.

[3]  L. Benet,et al.  Noncompartmental determination of the steady-state volume of distribution. , 1979, Journal of pharmaceutical sciences.

[4]  S. Wallace,et al.  Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. , 1982, Annals of internal medicine.

[5]  W J Jusko,et al.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.

[6]  G. Bonadonna,et al.  Distribution and excretion of adriamycin in man. , 1973, Biomedicine / [publiee pour l'A.A.I.C.I.G.].

[7]  R. Chlebowski,et al.  Adriamycin and methyl‐CCNU combination therapy in hepatocellular carcinoma: Clinical and pharmacokinetic aspects , 1981, Cancer.

[8]  J. Gross,et al.  Prediction of adriamycin disposition in cancer patients using a physiologic, pharmacokinetic model. , 1978, Cancer treatment reports.

[9]  G D Knott,et al.  Mlab--a mathematical modeling tool. , 1979, Computer programs in biomedicine.

[10]  R. Benjamin,et al.  Pharmacokinetics and metabolism of adriamycin in man , 1973, Clinical pharmacology and therapeutics.

[11]  R. I. Glazer,et al.  Cytokinetic and biochemical effects of 5-iminodaunorubicin in human colon carcinoma in culture. , 1982, Cancer research.

[12]  P. Wilkinson,et al.  Liquid Chromatographic Analysis of Adriamycin and Metabolites in Biological Fluids , 1978 .

[13]  S. Eksborg,et al.  Liquid chromatographic monitoring of daunorubicin and daunorubicinol in plasma from leukemic patients treated with daunorubicin or the daunorubicin-DNA complex , 2004, Cancer Chemotherapy and Pharmacology.

[14]  H. Eichholtz-Wirth,et al.  Dependence of the cytostatic effect of adriamycin on drug concenration and exposure time in vitro. , 1980, British Journal of Cancer.

[15]  R. Benjamin,et al.  Adriamycin chemotherapy—efficacy, safety, and pharmacologic basis of an intermittent single high‐dosage schedule , 1974, Cancer.

[16]  S K Carter,et al.  Adriamycin. A new anticancer drug with significant clinical activity. , 1974, Annals of internal medicine.

[17]  W. Creasey,et al.  Clinical effects and pharmacokinetics of different dosage schedules of adriamycin. , 1976, Cancer research.

[18]  D. Alberts,et al.  Pharmacologic studies of anticancer drugs with the human tumor stem cell assay , 2004, Cancer Chemotherapy and Pharmacology.

[19]  P. Wilkinson,et al.  The persistence of adriamycin in man and rat. , 1974, British journal of clinical pharmacology.

[20]  J. Willson,et al.  Inhibition of human ovarian cancer colony formation by adriamycin and its major metabolites. , 1980, Cancer research.

[21]  R. Benjamin,et al.  Biliary disposition of adriamycin , 1977 .

[22]  B. Drewinko,et al.  Survival kinetics of cultured human lymphoma cells exposed to adriamycin. , 1973, Cancer research.

[23]  R. Benjamin,et al.  Plasma pharmacokinetics of adriamycin and its metabolites in humans with normal hepatic and renal function. , 1977, Cancer research.